Table 3.
COX-2 positive cases | COX-2 negative cases | Sum | |
Entire study group (n = 104) | |||
C219 low [IRS 0–3] | 56 | 5 | 61 |
C219 high [IRS 4–12] | 2 | 41 | 43 |
Sum | 58 | 46 | 104 |
JSB-1 low [IRS 0–3] | 55 | 4 | 59 |
JSB-1 high [IRS 4–12] | 3 | 42 | 45 |
Sum | 58 | 46 | 104 |
Patients postoperatively treated only with chemotherapy (n = 28) | |||
C219 low [IRS 0–3] | 13 | 1 | 14 |
C219 high [IRS 4–12] | 1 | 13 | 14 |
Sum | 14 | 14 | 28 |
JSB-1 low [IRS 0–3] | 12 | 1 | 13 |
JSB-1 high [IRS 4–12] | 2 | 13 | 15 |
Sum | 14 | 14 | 28 |
COX-2, cyclooxygenase-2; MDR1/P-gp, MDR1/P-glycoprotein; IRS, immunoreactive score [17].